Browsing: Rhythms

Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted marketing authorization to Imcivree (setmelanotide) for acquired hypothalamic obesity (HO), making it the first approved therapy for this indication in Japan. Boston-based Rhythm Pharmaceuticals (Nasdaq: RYTM) holds the rights directly and said it expects a commercial launch before the end of 2026, pending final pricing…